B. Riley Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel has maintained a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) but lowered the price target from $29 to $25.

March 21, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B. Riley Securities maintains a Buy rating on Viridian Therapeutics but lowers the price target from $29 to $25.
The maintenance of a Buy rating by B. Riley Securities indicates continued confidence in Viridian Therapeutics' potential. However, the reduction in the price target from $29 to $25 suggests a recalibration of expectations, possibly due to market conditions or company-specific factors not detailed in the news. This mixed signal could lead to short-term uncertainty among investors, balancing optimism with a more conservative valuation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100